Fulcrum Therapeutics, Inc.
NASDAQ:FULCBiotechnology
+$0.06 today
- Market cap
- $284.14M
- Beta
- 2.92
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.00
Volume 0.63M
Average 1.78M
FULC Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Fulcrum Therapeutics, Inc.NASDAQ: FULC
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $8.1M rose 15.8% year over year, ahead of the -10.8% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 11.3% from the prior quarter. Over 3 fiscal years it compounded at -11.7% a year.
Context
- Selling, general & admin increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 5 analysts of $1.53M (-94.7%) for the fiscal year ending Dec 2026, a slowdown from the -21.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $8.1M+11.3% QoQ
- Last fiscal yearDec 2025
- $28.67M-21.4% YoY
- LTMMar 2026
- $29.77M-10.8% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 28.67M USD
- Year-over-year change
- -21.4%
- 4-year CAGR
- -1.6%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.67M | -21.4% |
| FY2024 | 2024-12-31 | 36.45M | -12.5% |
| FY2023 | 2023-12-31 | 41.67M | -0.1% |
| FY2022 | 2022-12-31 | 41.69M | +36.6% |
| FY2021 | 2021-12-31 | 30.52M | — |
Selling, General & Admin vs competitors
How FULC compares with its peers on the latest reported figures
- FULC's LTM Mar 2026 selling, general & admin of $29.77M is the 6th highest of the 10 companies compared; the peer median is $33.4M.
- Its year-over-year change of -10.8% is the 7th highest of 10, against a peer median of +3.6%.
- Over three fiscal years its annual growth of -11.7% compares with a peer median of +13.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $82.03M | +32.5% | — | 103.6% | |
| LTM Mar 2026 | $76.67M | +0.6% | +17.4% | 120.8% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $55.57M | -17.1% | +24.5% | — |
| LTM Mar 2026 | $34.94M | -61.3% | — | 50.2% | |
| LTM Mar 2026 | $33.4M | -31.3% | -6.4% | 337.6% | |
| LTM Mar 2026 | $29.77M | -10.8% | -11.7% | — | |
| LTM Mar 2026 | $29.24M | +9.4% | -8.0% | 654.9% | |
| LTM Mar 2026 | $27.57M | +8.0% | +40.7% | — | |
| LTM Mar 2026 | $18.69M | +3.6% | -6.4% | 126.4% | |
| LTM Mar 2026 | $18.51M | +10.2% | +13.1% | — | |
| Peer median (excluding FULC) | $33.4M | +3.6% | +13.1% | 123.6% | |
Competitors are the stored peer set for FULC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 19.16M | 6.34M | 2.81M | 80M | 0 |
| Cost of Revenue | 69.7M | 76.78M | 71.8M | 63.39M | 1.39M |
| Gross Profit | (50.54M) | (70.44M) | (69M) | 16.61M | (1.39M) |
| Gross Margin | -263.7% | -1110.7% | -2459.8% | 20.8% | — |
| Research & Development | 69.7M | 76.78M | 71.8M | 63.39M | 56.1M |
| Selling, General & Admin | 30.52M | 41.69M | 41.67M | 36.45M | 28.67M |
| Operating Expenses | 30.52M | 42.12M | 41.67M | 38.51M | 83.38M |
| Depreciation & Amortization | 2.52M | 2.41M | 2.17M | 1.59M | 1.39M |
| EBITDA | (78.33M) | (109.72M) | (95.16M) | (18.24M) | (73.49M) |
| EBITDA Margin | -408.8% | -1730.1% | -3392.6% | -22.8% | — |
| Operating Income | (81.05M) | (112.56M) | (110.66M) | (21.9M) | (84.77M) |
| Operating Margin | -423.0% | -1774.9% | -3945.2% | -27.4% | — |
| Interest Income | 207K | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 207K | 2.69M | 13.33M | 12.17M | 9.89M |
| Income Before Tax | (80.85M) | (109.87M) | (97.34M) | (9.73M) | (74.88M) |
| Pre-Tax Margin | -421.9% | -1732.4% | -3470.1% | -12.2% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (80.85M) | (109.87M) | (97.34M) | (9.73M) | (74.88M) |
| Net Margin | -421.9% | -1732.4% | -3470.1% | -12.2% | — |
| EPS (Basic) | (2.22) | (2.35) | (1.59) | (0.16) | (1.18) |
| EPS (Diluted) | (2.22) | (2.35) | (1.59) | (0.16) | (1.18) |
| Weighted Avg Shares | 35.36M | 44.99M | 61.31M | 61.98M | 63.36M |
| Weighted Avg Shares (Diluted) | 35.36M | 44.99M | 61.31M | 61.98M | 63.36M |
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
Intrinsic Alpha fair value
Locked
Current Price
$3.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.